RecruitingRecruiting
A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder
NCT07759128 · Otsuka Pharmaceutical Development & Commercialization, Inc.
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Compare the Efficacy and Safety of Fixed Doses of SEP-363856 to Placebo in the Treatment of Adults With Generalized Anxiety Disorder
About this study
This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, safety, and tolerability of fixed doses of SEP-363856 (50 and 75 milligrams per day \[mg/day\]) to placebo in adults at least 18 years of age with generalized anxiety disorder (GAD) over 8 weeks.
Eligibility criteria
Key Inclusion Criteria:
1. Male or female participants at least 18 years of age at the time of informed consent
2. Primary diagnosis of Generalized Anxiety Disorder (GAD) per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical psychiatric evaluation
3. Body Mass Index (BMI) between 18 and 40 kilograms per square meter (kg/m\^2) (inclusive)
4. Participant is willing and able to comply with study procedures and visit schedule
5. Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests
6. Willing and able to discontinue prohibited medications/therapies per protocol
7. i) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
8. Participant is willing and able to safely discontinue all prohibited medications/therapies/herbal supplements in accordance with the protocol-required washouts prior to baseline/Day 1 and during the trial period.
Key Exclusion Criteria:
1. Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
2. Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
3. Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
4. Significant suicide risk (e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale \[C-SSRS\] or MADRS)
5. Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
6. Prior exposure to restricted treatments
7. Pregnant or breastfeeding females
8. Participation in another investigational study within 180 days (or more than \[\>\] 1 trial in last year)
9. Known history of human immunodeficiency virus seropositivity, hepatitis B or C
Study design
Enrollment target: 576 participants
Allocation: randomized
Masking: triple
Age groups: adult, older_adult
Timeline
Starts: 2026-07-28
Estimated completion: 2028-12-13
Last updated: 2026-11-16
Interventions
Drug: SEP-363856Other: Placebo
Primary outcomes
- • Change From Baseline at Week 8 in Hamilton Anxiety Rating Scale (HAM-A) Total Score (Baseline, Week 8)
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. · industry
Contacts & investigators
ContactOtsuka Call Center · contact · ProfessionalServices@otsuka-us.com · 844-687-8522
All locations (27)
The Center for Clinical TrialsRecruiting
Saraland, Alabama, United States
Del Sol Research ManagementRecruiting
Tucson, Arizona, United States
Pharmacology Research InstituteRecruiting
Encino, California, United States
California Neuroscience Research Medical Group, IncRecruiting
Sherman Oaks, California, United States
Next Level TrialsRecruiting
West Covina, California, United States
Emerson Clinical Research Institute - Washington, DCRecruiting
Washington D.C., District of Columbia, United States
Sarkis Clinical Trials - GainesvilleRecruiting
Gainesville, Florida, United States
Clinical Neuroscience Solutions, LLCRecruiting
Jacksonville, Florida, United States
Accel Research Sites - MaitlandRecruiting
Maitland, Florida, United States
CenExel Decatur GARecruiting
Decatur, Georgia, United States
AMR-Baber Research IncRecruiting
Naperville, Illinois, United States
AMR Conventions Research, IncRecruiting
Warrenville, Illinois, United States
Research Works, IncRecruiting
New Orleans, Louisiana, United States
Adams Clinical BostonRecruiting
Boston, Massachusetts, United States
Boston Clinical TrialsRecruiting
Boston, Massachusetts, United States
Vitalix Clinical (Worcester, MA)Recruiting
Worcester, Massachusetts, United States
Vector Clinical Trials - Las VegasRecruiting
Las Vegas, Nevada, United States
Integrative Clinical Trials LLCRecruiting
Brooklyn, New York, United States
Adams Clinical HarlemRecruiting
New York, New York, United States
Manhattan Behavioral Medicine PLLCRecruiting
New York, New York, United States
New Hope Clinical ResearchRecruiting
Charlotte, North Carolina, United States
Insight Clinical TrialsRecruiting
Independence, Ohio, United States
Sooner Clinical Research, Inc.Recruiting
Oklahoma City, Oklahoma, United States
FutureSearch Trials of DallasRecruiting
Dallas, Texas, United States
Adams Clinical DallasRecruiting
DeSoto, Texas, United States
Earle ResearchRecruiting
Friendswood, Texas, United States
Family Psychiatry of the WoodlandsRecruiting
The Woodlands, Texas, United States